What is Pendulum Therapeutics?
Pendulum Therapeutics stands as the first evidence-based microbiome company to utilize high-resolution, long-read DNA sequencing for the development of targeted interventions. Headquartered in San Francisco, the firm focuses on identifying microbiome mechanisms of action to address specific health conditions, most notably through its flagship product, Pendulum Glucose Control. This medical probiotic is designed to assist in the dietary management of blood sugar and A1C levels for individuals with type 2 diabetes. By integrating deep microbiology, biochemistry, and computational expertise, the company has established a unique competitive moat in the rapidly evolving field of precision medicine and gut health.
How much funding has Pendulum Therapeutics raised?
Pendulum Therapeutics has raised a total of $117.5M across 4 funding rounds:
Series A
$18.5M
Series B
$35M
Series C
$54M
Other Financing Round
$10M
Series A (2017): $18.5M with participation from True Ventures, Morgan Noble, and Khosla Ventures
Series B (2019): $35M led by Sequoia Capital
Series C (2021): $54M supported by True Ventures, Steamboat Ventures, Meritech, and Khosla Ventures
Other Financing Round (2023): $10M featuring Fonterra
Key Investors in Pendulum Therapeutics
Sequoia Capital
A premier global venture capital firm with an unparalleled track record of partnering with entrepreneurs to create market-leading companies across the technology and healthcare sectors.
Khosla Ventures
A venture firm founded by Vinod Khosla that provides strategic advice and capital to entrepreneurs working on breakthrough technologies in health, AI, and sustainable energy.
True Ventures
A founder-first venture capital firm that partners with creative teams at the earliest stages to build enduring technology and science-driven companies.
What's next for Pendulum Therapeutics?
With the recent influx of capital, Pendulum Therapeutics is well-positioned to scale its clinical validation efforts and expand its commercial footprint. The company's strategic roadmap likely involves deepening its research into additional metabolic and chronic disease pathways, leveraging its proprietary platform to identify new therapeutic targets. As the firm moves into its next phase of growth, the focus will remain on maintaining its status as a leader in the medical probiotic space while navigating the complexities of clinical regulatory pathways and market adoption. The continued support from institutional investors suggests a high degree of confidence in the company's ability to translate complex genomic data into scalable, patient-centric health solutions.
See full Pendulum Therapeutics company page
